
News Treatment Extends Lives of Advanced Bladder Cancer Patients
Two new treatments are proving to be the most effective treatment in decades for some people with bladder cancer, according to groundbreaking trial results in two separate studies. Researchers found that in both trials, patients who received a combination of immunotherapy drugs lived longer than those who received standard chemotherapy treatment, marking a never-before-seen improvement in treatment for advanced bladder cancer. The advancements are seen as “monumental” in urology, Dr. Andrea Apolo of the National Cancer Institute’s Genitourinary Malignancies Branch said in a press release. “The future looks bright for our patients.” New Standard of Care One promising treatment combines enfortumab vedotin (Padcev) and the immunotherapy drug pembrolizumab (Keytruda). Researchers found the combination, known as an antibody-drug conjugate, proved especially potent in reducing cancer and extending the lives of cancer patients. In a trial called EV-302, patients received either the antibody-drug conjugate or standard chemotherapy. The study compared how an antibody-drug conjugate works to drugs usually used to treat advanced bladder cancer....
